NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
08/10/2026
Back to search
Official data from USPTO
BTG
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
72
Latest update
08/10/2026
Trademark type
Word
Nice classes
5, 10
Filing date
08/18/2014
Registration date
05/24/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/10/2026
Last transaction
08/10/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
24
Owner location
London, GB
Examiner
JACKSON, ELIZABETH FLEMING
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
PROTHERICS MEDICINES DEVELOPMENT LIMITED
BTG International Limited
BTG International Limited
Representatives
Jonathan A. Hyman Knobbe, Martens, Olson & Bear, LLP
Technical classification
Nice Classes
Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalmedicinal and veterinary preparations and substancesvaccinesantitoxic serapharmaceutical preparations for the treatment of cancerpharmaceutical preparations and substances for the treatment of thrombosisembolismsinflammationautoimmune diseasepharmaceutical preparations for the treatment of envenomation by snakesveterinary preparations for the treatment of envenomation by snakesdietetic foods adapted for medical usefood supplements containing vitaminsmineralstrace elementsoils and fatseither apart or in combinations thereof for use in the treatment of cardiovascular issuesvascular issues or cancerliquid medical sealantsliquid adhesives for use in surgical and clinical procedure; pharmaceutical and medicinal preparations and substancesvaccines and vaccine adjuvantsproteinspeptidessera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomationoverdose of toxic substancessepsis ; drug delivery agentspreparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substancesdrug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations and substances for use in the circulatory system; pharmaceutical preparations and substances for embolisation; pharmaceutical preparations and substances for embolisation of tumours and arteriovenous malformations (AVMs); pharmaceutical preparations and substances for use in the circulatory system for the treatment of tumours and AVMs; adjuvants for medicinal purposesvaccine adjuvants and vaccine preparations containing adjuvant; chemical reagents for medical and veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemico-pharmaceutical preparations for the treatment of envenomation by snakes; chemical preparations for medical and pharmaceutical purposes for the treatment of envenomation by snakes; medicines for the treatment of envenomation by snakes; pharmaceutical and veterinary preparations for the treatment of digoxindigitalis and other cardio-active glycoside toxicity; pharmaceutical and veterinary preparations for the treatment of pre-eclampsia; chemical reagents for medical and veterinary therapeutic and diagnostic purposes; chemico-pharmaceutical preparations for use in the treatment of digoxindigitalis and other cardio-active glycoside toxicityfor use in the treatment of pre-eclampsia; chemical preparations for medical and pharmaceutical purposes and medicines for use in the treatment of digoxindigitalis and other cardio-active glycoside toxicity and for use in the treatment of pre-eclampsia; transarterial chemoembolisation pharmaceutical preparationsvaccines and sera; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substancestherapeutic agents for delivery of radioactive materials to target sites within the body for the treatment of cancer; irradiated and radioactive microspheres used for in vivo therapeutic medical purposesbeads in the nature of microscopic glass beads impregnated with radioactive pharmaceutical preparations for treatment of cancerous tumors; radiotherapy substances for medical purposesradioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiopharmaceuticalsradiopharmaceuticals for the treatment of cancer and radiopharmaceutical preparations for use in nuclear medicine; therapeutic agents for delivery of radioactive material to target sites within the body; beadsincluding microscopic radioactive beads featuring pharmaceutical preparations for treatment of cancerous tumours; beadsincluding microscopic glass beadsimpregnated with radioactive pharmaceutical preparations and consisting of radioactive material for treatment of cancerous tumours; radioactive glass beads impregnated with pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use with ultrasound waves to enhance drug delivery and medically activate drugs; pharmaceutical preparations in the form of foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams for use in producing foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams and for use in preparing foamsfor sclerotherapyphlebologyangiology and proctologyfor the treatment of oesophageal variceshydrocelesin sterilisation treatment and for treatment of varicose veinsarterio-venous malformations; pharmaceutical preparations containing methotrexate antidotes; pharmaceutical preparations containing 5-fluorouracil antidotes; pharmaceutical preparations for use in chemotherapy and for the treatment of autoimmune diseases ; pharmaceutical preparations used for regulating toxicity levels of therapeutic agents; pharmaceutical preparations used for depleting concentrations of therapeutic agents
Class 10
Surgicalmedical and veterinary apparatus and instrumentsmedical syringessurgical and medical apparatus for producing and administering pharmaceutical foamssurgical and medical apparatus for producing foams for treatment of varicose veinsarterio-venous malformationsoesophageal varices and hydrocelesdevices for intravenous administration of pharmaceutical foamdiagnostic devices for grading the severity of venous conditionssnake envenomation and toxic drugs overdose; surgicalmedical and veterinary apparatus and instrumentsmedical devices for use in pulmonary and thoracic surgery and procedureslung air trapping reduction coilslung volume reduction devicessurgical implants comprising artificial materialsurgical implants comprising artificial materials for restoringmaintaining and improving patient breathing and artificial surgical implants for restoringmaintaining and improving lung functioncatheters for deploying these; surgicalmedical and veterinary apparatus and instrumentsmedical deviceapparatus and instruments for treating cancer; drug delivery embolisation apparatusinstruments and systems; apparatus and instruments for use in the circulatory systemcathetersinjection syringes and sealed vials; medical apparatus and instruments for embolisation; surgical and medical apparatus and instrumentscathetersinjection syringes and sealed vial devices for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; embolisation apparatusinstruments and systems comprising surgical and medical instruments for embolizationembolic devices for use in treating cancer and tumorsembolic devices for treating arteriovenous malformations (AVMs) of the bodyembolic devices for use in treating tumors; drug delivery embolisation systems; drug delivery apparatus and instruments namelya drug delivery system comprised of injection syringes and sealed vials; injection syringes for use with catheters; apparatus and instruments for use in the circulatory systemcathetersinjection syringes and sealed vials for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; medical apparatus and instruments for embolizationmedical devices in the nature of embolic microspheres for embolization; surgical and medical apparatus and instruments for embolisationembolisation apparatusinstruments and systems comprising microspheres and injection syringes for use in blood vessels and the circulatory system to carry out embolisation; radiotherapy apparatus; surgical and medical apparatus and instruments for delivery of radiopharmaceuticals and radioactive material to target sites within the body; beadsmicroscopic radioactive glass beads administered surgically for treatment of cancerous tumours; radioactive beadsradioactive glass beads administered for treatment of cancerous tumours; surgical and medical apparatus and instruments for use in the circulatory system ; medical devices in the nature of drug delivery systems which use ultrasound to enhance drug delivery and medically activate drugs; catheters for delivery of drugs and fluids sold together as a unit with controllers and power units for infusion catheters; ultrasonic drug delivery and drug activation apparatus sold together as a unit with controllers and power units therefor; needles for medical usecannula needles; medical tubing for sclerotherapy; medical tubing for the treatment of varicose veinsvenous malformationsarterio-venous malformationsoesophageal varices and hydroceles; surgical and medical apparatus for producing and administering foams for the treatment of varicose veinsvenous malformationsarterio-venous malformationsoesophageal varices and hydroceles; surgical and medical apparatus for producing and administering sclerosing foams for the treatment of varicose veinsvenous malformationsarterio-venous malformationsoesophageal varices and hydroceles; surgical and medical apparatus for producing and administering foams for use in sclerotherapyphlebologyangiology and proctology; syringes for producing and administering foams for use in sclerotherapyphlebologyangiology and proctology; surgical and medical apparatus for administering and producing foams for use in sterilisation treatment; surgical and medical apparatus for use in treatment of varicose veinsarterio-venous malformationsoesophageal varices and hycroceles; syringes for use in treatment of varicose veinsarterio-venous malformationsoesophageal varices and hydroceles; devices for assessing the physical characteristics of such foamsmedical diagnostic apparatus for analyzing the efficacy of sclerotherapy foams for medical purposes; medical devices for intravenous administration of sclerosing foam for the treatment of varicose veinsvenous malformationsarterio-venous malformationsoesophageal varices and hydroceles; medical devices for monitoring the position and effect of sclerosing foam in the human body for the treatment of varicose veinsvenous malformationsarterio-venous malformationsoesophageal varices and hydroceles; medical diagnostic apparatus for diagnosing all the above medical conditionsvaricose veinsarterio-venous malformationsoesophageal varicesspider veins hydrocelescancertumorscirculatory system conditions and pulmonary and thoracic conditions; compression bandages; component parts and fittings for all of the aforesaid goods; irradiated or radioactive microspheres used for in vivo therapeutic medical purposesimplantable radiation therapy devices consisting of radioactive beads in the nature of microscopic radioactive beads for treatment of cancerous tumours; implantable radiation therapy devices consisting of radioactive beads and a bioabsorbable carrier assemblybeads in the nature of microscopic radioactive beads for treatment of cancerous tumours and beads in the nature of radioactive microscopic glass beads for treatment of cancerous tumours; radioactive glass beadsimplantable radiation therapy devices consisting of radioactive beads and a bioabsorbable carrier assembly and implantable radiation therapy devices consisting of radioactive beads; radioactive glass beadsimplantable radiation therapy devices consisting of radioactive glass beads administered for treatment of cancerous tumours
Publications
History of USPTO decisions and trademark events.
72 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
08/10/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
08/10/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/24/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
05/26/2026
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
05/24/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/14/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/14/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/14/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/14/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/14/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/13/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/13/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/13/2023
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
04/11/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
04/11/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/07/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/16/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/16/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/16/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/16/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/16/2023
E815
TEAS SECTION 8 & 15 RECEIVED
09/28/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/12/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/12/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/12/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/12/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/12/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/12/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/30/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/30/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/30/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/30/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/30/2021
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
05/24/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/22/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/29/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/29/2020
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
08/29/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/29/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/29/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/29/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
05/24/2016
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
04/14/2016
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/03/2016
IUCN
NOTICE OF ALLOWANCE CANCELLED
02/22/2016
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
02/22/2016
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/01/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/07/2015
PUBO
PUBLISHED FOR OPPOSITION
07/07/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/17/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/01/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/01/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/28/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/27/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/27/2015
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
04/13/2015
GPRA
PRIORITY ACTION E-MAILED
04/13/2015
CPRA
PRIORITY ACTION WRITTEN
04/13/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/21/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/20/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/20/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/21/2014
GNRT
NON-FINAL ACTION E-MAILED
11/21/2014
CNRT
NON-FINAL ACTION WRITTEN
11/21/2014
DOCK
ASSIGNED TO EXAMINER
11/14/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/29/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/29/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/29/2014
ALIE
ASSIGNED TO LIE
08/22/2014
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
08/21/2014
NWAP
NEW APPLICATION ENTERED
08/21/2014
Continuous trademark protection
Get notified about every new filing that threatens BTG or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.